Prediction Model for Response to Biologics and Small Molecular Agent for UC
NCT05186623
·
clinicaltrials.gov ↗
RECRUITING
Status
300
Enrollment
OTHER
Sponsor class
Conditions
Ulcerative Colitis
Interventions
DRUG:
Vedolizumab, Ustekinumab, or Tofacitinib
Sponsor
Asan Medical Center